Seeking Alpha

Sarepta Therapeutics (SRPT) says eteplirsen (I, II) continues to show promise in improving the...

Sarepta Therapeutics (SRPT) says eteplirsen (I, II) continues to show promise in improving the walking ability of Duchenne muscular dystrophy patients after 84 weeks. Shares +4% premarket. (PR)
From other sites
Comments (1)
  • whaddyamean?
    , contributor
    Comments (514) | Send Message
     
    "Continues to show promise" results in a 4% premarket pop?

     

    Now that I've done my due diligence, it's time to pull the trigger!

     

    Don't you just love these biotechs?
    19 Jun 2013, 09:03 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs